| Host: |
CHO cells |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-MERS Nucleocapsid protein-protein was developed from cho cells. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
| Dilution Range: |
Spin the vial and reconstite in distilled water to a concentration not less than 0.1 mg/mL. This can then be diluted into other buffers. |
| Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunogen Region: |
RBD |
| Immunogen: |
DNA sequence encoding the receptor binding domain of MERS-CoV Nucleoprotein including a C-terminal His tag was expressed in CHO Cells. NA |
| Background | Recombinant MERS-CoV Nucleocapsid is a protein consisting of amino acid residues [1-413], due to glycosylation migrates as an approximately 46 kDa protein on SDS-PAGE. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
